본문 바로가기
KERD
논문KCI 등재

Forthcoming Step in Gastric Cancer Prevention: How Can Risk Stratification Be Combined with Endoscopic Screening for Gastric Cancer?

Hamashima Chisato
거트앤리버 소화기연관학회협의회|2022.11|Gut and Liver|제16권 제6호|pp. 811-824|DOI 10.5009/gnl210313

1

조회

0

다운로드

0

인용

0

참고문헌

키워드

Mass screeningEndoscopesStomach neoplasmsHelicobacter pylori antibodiesSerum pepsinogens

초록

Although the concern for gastric cancer prevention has increased, gastric cancer has remained a heavy burden worldwide and is not just a local issue in East Asian countries. However, as several screening programs (listed below) have shown some success, it is important to determine whether the situation is changing in some other countries and whether similar methods should be recommended. Endoscopic screening has been performed as a national program in South Korea and Japan, and the results have shown a reduction in gastric cancer mortality. Although the efficacy of Helicobacter pylori eradication has been established, the efficacy of the screen-and-treat strategy is presently being evaluated in randomized controlled trials. The serum pepsinogen test and endoscopic examination can divide high-risk subjects with severe gastric atrophy from average-risk subjects. Risk stratification is anticipated to contribute to an efficient method of prediction of gastric cancer development when combined with endoscopic screening. Countries with a high incidence rate should realize the immediate need to reduce gastric cancer death directly by endoscopic screening and should recognize screen-and-treat as a second option to reduce future risk. However, all forms of gastric cancer prevention programs have some harms and potential to increase unnecessary examinations. A balance of the benefits and harms should be always considered. Although further study is needed to obtain sufficient evidence for gastric cancer prevention, the best available method should be examined in the context of each country.

Abstract

Although the concern for gastric cancer prevention has increased, gastric cancer has remained a heavy burden worldwide and is not just a local issue in East Asian countries. However, as several screening programs (listed below) have shown some success, it is important to determine whether the situation is changing in some other countries and whether similar methods should be recommended. Endoscopic screening has been performed as a national program in South Korea and Japan, and the results have shown a reduction in gastric cancer mortality. Although the efficacy of Helicobacter pylori eradication has been established, the efficacy of the screen-and-treat strategy is presently being evaluated in randomized controlled trials. The serum pepsinogen test and endoscopic examination can divide high-risk subjects with severe gastric atrophy from average-risk subjects. Risk stratification is anticipated to contribute to an efficient method of prediction of gastric cancer development when combined with endoscopic screening. Countries with a high incidence rate should realize the immediate need to reduce gastric cancer death directly by endoscopic screening and should recognize screen-and-treat as a second option to reduce future risk. However, all forms of gastric cancer prevention programs have some harms and potential to increase unnecessary examinations. A balance of the benefits and harms should be always considered. Although further study is needed to obtain sufficient evidence for gastric cancer prevention, the best available method should be examined in the context of each country.

참고문헌 (96)

  1. "Cancer Today, 2020" (2020)[URL]
  2. Shah SC, "Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older", Gastroenterology, 159, pp.1705~1714 (2020)
  3. Huang RJ, "Disaggregated mortality from gastrointestinal cancers in Asian Americans : analysis of United States death records", Int J Cancer, 148, pp.2954~2963 (2021)
  4. Liou JM, "Screening and eradication of Helicobacter pylori for gastric cancer prevention : the Taipei global consensus", Gut, 69, pp.2093~2112 (2020)
  5. Cuschieri K, "Eurogin roadmap 2017 : triage strategies for the management of HPVpositive women in cervical screening programs", Int J Cancer, 143, pp.735~745 (2018)
  6. Chen LS, "Baseline faecal occult blood concentration as a predictor of incident colorectal neoplasia : longitudinal follow-up of a Taiwanese population-based colorectal cancer screening cohort", Lancet Oncol, 12, pp.551~558 (2011)
  7. 박현아, "위암 검진 권고안", 대한의사협회지, 58(5), pp.373~384 (2015), 대한의사협회[DOI]
  8. Hamashima C, "Update version of the Japanese Guidelines for Gastric Cancer Screening", Jpn J Clin Oncol, 48, pp.673~683 (2018)
  9. Hamashima C, "Cancer screening guidelines and policy making : 15 years of experience in cancer screening guideline development in Japan", Jpn J Clin Oncol, 48, pp.278~286 (2018)
  10. Song M, "Age and sex interactions in gastric cancer incidence and mortality trends in Korea", Gastric Cancer, 18, pp.580~589 (2015)
  11. Katanoda K, "Updated trends in cancer in Japan : incidence in 1985-2015 and mortality in 1958-2018-a sign of decrease in cancer incidence", J Epidemiol, 31, pp.426~450 (2021)
  12. Huang RJ, "A summary of the 2020 Gastric Cancer Summit at Stanford University", Gastroenterology, 159, pp.1221~1226 (2020)
  13. Liou JM, "The optimal age threshold for screening upper endoscopy for uninvestigated dyspepsia in Taiwan, an area with a higher prevalence of gastric cancer in young adults", Gastrointest Endosc, 61, pp.819~825 (2005)
  14. Leung WK, "Screening for gastric cancer in Asia : current evidence and practice", Lancet Oncol, 9, pp.279~287 (2008)
  15. Kim Y, "Overview of the National Cancer Screening Programme and the cancer screening status in Korea", Asian Pac J Cancer Prev, 12, pp.725~730 (2011)
  16. Lee YC, "The benefit of mass eradication of Helicobacter pylori infection : a community-based study of gastric cancer prevention", Gut, 62, pp.676~682 (2013)
  17. Chen Q, "Effectiveness of endoscopic gastric cancer screening in a rural area of Linzhou, China : results from a case-control study", Cancer Med, 5, pp.2615~2622 (2016)
  18. Gotoda T, "Randomized controlled trial comparing gastric cancer screening by gastrointestinal X-ray with serology for Helicobacter pylori and pepsinogens followed by gastrointestinal endoscopy", Gastric Cancer, 18, pp.605~611 (2015)
  19. Xiao HF, "Community-based upper gastrointestinal cancer screening in a randomized controlled trial: baseline results in a non-high-incidence area", Cancer Prev Res(Phila), 13, pp.317~328 (2020)
  20. Riecken B, "No impact of repeated endoscopic screens on gastric cancer mortality in a prospectively followed Chinese population at high risk", Prev Med, 34, pp.22~28 (2002)
  21. 김희원, "Effectiveness of Gastric Cancer Screening on Gastric Cancer Incidence and Mortality in a Community-Based Prospective Cohort", Cancer Research and Treatment, 50(2), pp.582~589 (2018), 대한암학회
  22. Suh YS, "National cancer screening program for gastric cancer in Korea : nationwide treatment benefit and cost", Cancer, 126, pp.1929~1939 (2020)
  23. Matsumoto S, "Results of mass endoscopic examination for gastric cancer in Kamigoto Hospital, Nagasaki Prefecture", World J Gastroenterol, 13, pp.4316~4320 (2007)
  24. Hosokawa O, "Decreased death from gastric cancer by endoscopic screening : association with a population-based cancer registry", Scand J Gastroenterol, 43, pp.1112~1115 (2008)
  25. Hamashima C, "Mortality reduction from gastric cancer by endoscopic and radiographic screening", Cancer Sci, 106, pp.1744~1749 (2015)
  26. Hamashima C, "Impact of endoscopic screening on mortality reduction from gastric cancer", World J Gastroenterol, 21, pp.2460~2466 (2015)
  27. Hamashima C, "A community-based, case-control study evaluating mortality reduction from gastric cancer by endoscopic screening in Japan", PLoS One, 8, pp.e79088~ (2013)
  28. Matsumoto S, "Efficacy of endoscopic screening in an isolated island : a case-control study", Indian J Gastroenterol, 33, pp.46~49 (2014)
  29. Jun JK, "Effectiveness of the Korean National Cancer Screening Program in reducing gastric cancer mortality", Gastroenterology, 152, pp.1319~1328 (2017)
  30. Zhang X, "Endoscopic screening in Asian countries is associated with reduced gastric cancer mortality : a meta-analysis and systematic review", Gastroenterology, 155, pp.347~354 (2018)
  31. Hamashima C, "Benefits and harms of endoscopic screening for gastric cancer", World J Gastroenterol, 22, pp.6385~6392 (2016)
  32. Hamashima C, "Quality assurance manual of endoscopic screening for gastric cancer in Japanese communities", Jpn J Clin Oncol, 46, pp.1053~1061 (2016)
  33. Hamashima C, "Sensitivity of endoscopic screening for gastric cancer by the incidence method", Int J Cancer, 133, pp.653~659 (2013)
  34. Hubbard RA, "The cumulative risk of false-positive fecal occult blood test after 10 years of colorectal cancer screening", Cancer Epidemiol Biomarkers Prev, 22, pp.1612~1619 (2013)
  35. Hamashima C, "Comparison of observed and expected numbers of detected cancers in the research center for cancer prevention and screening program", Jpn J Clin Oncol, 36, pp.301~308 (2006)
  36. Harris RP, "A value framework for cancer screening : advice for high-value care from the American College of Physicians", Ann Intern Med, 162, pp.712~717 (2015)
  37. Hamashima C, "Potential capacity of endoscopic screening for gastric cancer in Japan", Cancer Sci, 108, pp.101~107 (2017)
  38. SeeffLC, "How many endoscopies are performed for colorectal cancer screening? Results from CDC’s survey of endoscopic capacity", Gastroenterology, 127, pp.1670~1677 (2004)
  39. SeeffLC, "Is there endoscopic capacity to provide colorectal cancer screening to the unscreened population in the United States", Gastroenterology, 127, pp.1661~1669 (2004)
  40. van Turenhout ST, "Anticipating implementation of colorectal cancer screening in the Netherlands : a nation wide survey on endoscopic supply and demand", BMC Cancer, 12, pp.46~ (2012)
  41. Joseph DA, "Colorectal cancer screening : estimated future colonoscopy need and current volume and capacity", Cancer, 122, pp.2479~2486 (2016)
  42. Comas M, "Long-term prediction of the demand of colonoscopies generated by a population-based colorectal cancer screening program", PLoS One, 11, pp.e0164666~ (2016)
  43. Andermann A, "Revisiting Wilson and Jungner in the genomic age : a review of screening criteria over the past 40 years", Bull World Health Organ, 86, pp.317~319 (2008)
  44. Helicobacter pylori eradication as a strategy for preventing gastric cancer:IARC Working Group Report Volume 8, "IARC Helicobacter pylori Working Group", International Agency for Research on Cancer, ~ (2014)
  45. O’Connor A, "Population screening and treatment of Helicobacter pylori infection", Nat Rev Gastroenterol Hepatol, 14, pp.230~240 (2017)
  46. Correa P, "Human gastric carcinogenesis : a multistep and multifactorial process : First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention", Cancer Res, 52, pp.6735~6740 (1992)
  47. Hamashima C, "Receiver operating characteristic analysis of prediction for gastric cancer development using serum pepsinogen and Helicobacter pylori antibody tests", BMC Cancer, 17, pp.183~ (2017)
  48. Terasawa T, "Prediction of gastric cancer development by serum pepsinogen test and Helicobacter pylori seropositivity in Eastern Asians : a systematic review and meta-analysis", PLoS One, 9, pp.e109783~ (2014)
  49. Kuo YT, "Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region : a systematic review and meta-analysis", Lancet Gastroenterol Hepatol, 2, pp.707~715 (2017)
  50. Savoldi A, "Prevalence of antibiotic resistance in Helicobacter pylori : a systematic review and meta-analysis in World Health Organization regions", Gastroenterology, 155, pp.1372~1382 (2018)
  51. Lane JA, "Randomised clinical trial : Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study", Aliment Pharmacol Ther, 33, pp.922~929 (2011)
  52. Wu JC, "Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease : a double blind, placebo controlled, randomised trial", Gut, 53, pp.174~179 (2004)
  53. Ma JL, "Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality", J Natl Cancer Inst, 104, pp.488~492 (2012)
  54. Wong BC, "Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China : a randomized controlled trial", JAMA, 291, pp.187~194 (2004)
  55. Wong BC, "Effects of selective COX-2inhibitor and Helicobacter pylori eradication on precancerous gastric lesions", Gut, 61, pp.812~818 (2012)
  56. Zhou L, "Relationship of Helicobacter pylori eradication with gastric cancer and gastric mucosal histological changes: a 10-year follow-up study", Chin Med J(Engl), 127, pp.1454~1458 (2014)
  57. Saito D, "Impact of H-pylori eradication on gastric atrophy: current status of the Japanese intervention trial (JITHP study)", Paper presented at: 6th International Gastric Cancer Congress, pp.131~136 (2005)
  58. Correa P, "Chemoprevention of gastric dysplasia : randomized trial of antioxidant supplements and anti-helicobacter pylori therapy", J Natl Cancer Inst, 92, pp.1881~1888 (2000)
  59. Tang J, "The effects of Helicobacter pylori eradication on histological changes of gastric mucosa and gastric cancer incidence : a three-year follow-up study", Mod Dig Intervention, 15, pp.47~49 (2010)
  60. Ford AC, "Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals : systematic review and meta-analysis of randomised controlled trials", BMJ, 348, pp.g3174~ (2014)
  61. Lee YC, "Association between Helicobacter pylori eradication and gastric cancer incidence : a systematic review and meta-analysis", Gastroenterology, 150, pp.1113~1124 (2016)
  62. Chen HN, "Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia : evidence from a meta-analysis", Gastric Cancer, 19, pp.166~175 (2016)
  63. Terasawa T, "Helicobacter pylori eradication treatment for gastric carcinoma prevention in asymptomatic or dyspeptic adults : systematic review and Bayesian meta-analysis of randomised controlled trials", BMJ Open, 9, pp.e026002~ (2019)
  64. Chiang TH, "Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality : a long-term cohort study on Matsu Islands", Gut, 70, pp.243~250 (2021)
  65. Leja M, "Multicentric randomised study of Helicobacter pylori eradication and pepsinogen testing for prevention of gastric cancer mortality : the GISTAR study", BMJ Open, 7, pp.e016999~ (2017)
  66. Lee YC, "Community-based gastric cancer screening coupled with a National Colorectal Cancer Screening Program : baseline results", Gastroenterology, 160, pp.2159~2161 (2021)
  67. "ISRCTN registry. ISRCTN71557037: Helicobacter pylori screening study" (2019)[URL]
  68. Hattori Y, "Sensitivity and specificity of mass screening for gastric cancer using the measurment of serum pepsinogens", Jpn J Cancer Res, 86, pp.1210~1215 (1995)
  69. Kitahara F, "Accuracy of screening for gastric cancer using serum pepsinogen concentrations", Gut, 44, pp.693~697 (1999)
  70. Song M, "Serum pepsinogen 1 and anti-Helicobacter pylori IgG antibodies as predictors of gastric cancer risk in Finnish males", Aliment Pharmacol Ther, 47, pp.494~503 (2018)
  71. Ohata H, "Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer", Int J Cancer, 109, pp.138~143 (2004)
  72. Yanaoka K, "Cancer highrisk subjects identified by serum pepsinogen tests : outcomes after 10-year follow-up in asymptomatic middle-aged males", Cancer Epidemiol Biomarkers Prev, 17, pp.838~845 (2008)
  73. Baak LC, "Weekend treatment with 20 and 40 mg omeprazole : effect on intragastric pH, fasting and postprandial serum gastrin, and serum pepsinogens", Gut, 32, pp.977~982 (1991)
  74. Baak LC, "Repeated intravenous bolus injections of omeprazole : effects on 24-hour intragastric pH, serum gastrin, and serum pepsinogen A and C", Scand J Gastroenterol, 26, pp.737~746 (1991)
  75. Shan J, "High serum pepsinogen I and beta Helicobacter pylori infection are risk factors for aspirin-induced gastroduodenal injury", Dig Dis, 36, pp.66~71 (2018)
  76. SamloffIM, "A study of the relationship between serum group I pepsinogen levels and gastric acid secretion", Gastroenterology, 69, pp.1196~1200 (1975)
  77. Iijima K, "Identification of a high-risk group for low-dose aspirin-induced gastropathy by measuring serum pepsinogen in H. pylori-infected subjects", J Gastroenterol, 50, pp.305~312 (2015)
  78. Yanaoka K, "Eradication of Helicobacter pylori prevents cancer development in subjects with mild gastric atrophy identified by serum pepsinogen levels", Int J Cancer, 125, pp.2697~2703 (2009)
  79. Ohkusa T, "Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of Helicobacter pylori: comparison with H. pylorinegative patients", Aliment Pharmacol Ther, 20(Suppl 1), pp.25~32 (2004)
  80. Haneda M, "Identification of a high risk gastric cancer group using serum pepsinogen after successful eradication of Helicobacter pylori", J Gastroenterol Hepatol, 28, pp.78~83 (2013)
  81. Chiang TH, "Risk stratification for gastric cancer after Helicobacter pylori eradication : a population-based study on Matsu Islands", J Gastroenterol Hepatol, 36, pp.671~679 (2021)
  82. Siurala M, "Studies of patients with atrophic gastritis : a 10-15-year follow-up", Scand J Gastroenterol, 1, pp.40~48 (1966)
  83. Meister H, "Gastritis, intestinal metaplasia and dysplasia versus benign ulcer in stomach and duodenum and gastric carcinoma : a histotopographical study", Pathol Res Pract, 164, pp.259~269 (1979)
  84. Sipponen P, "Gastric cancer risk in chronic atrophic gastritis : statistical calculations of cross-sectional data", Int J Cancer, 35, pp.173~177 (1985)
  85. Testoni PA, "Gastric cancer in chronic atrophic gastritis : associated gastric ulcer adds no further risk", J Clin Gastroenterol, 9, pp.298~302 (1987)
  86. Tatsuta M, "Fundal atrophic gastritis as a risk factor for gastric cancer", Int J Cancer, 53, pp.70~74 (1993)
  87. Kimura K, "An endoscopic recognition of the atrophic border and its significance in chronic gastritis", Endoscopy, 1, pp.87~97 (1969)
  88. Sugano K, "Kyoto global consensus report on Helicobacter pylori gastritis", Gut, 64, pp.1353~1367 (2015)
  89. Mera R, "Long term follow up of patients treated for Helicobacter pylori infection", Gut, 54, pp.1536~1540 (2005)
  90. Kamada T, "Clinical features of gastric cancer discovered after successful eradication of Helicobacter pylori : results from a 9-year prospective follow-up study in Japan", Aliment Pharmacol Ther, 21, pp.1121~1126 (2005)
  91. Kodama M, "Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication", J Gastroenterol, 47, pp.394~403 (2012)
  92. Kaji K, "Grading of atrophic gastritis is useful for risk stratification in endoscopic screening for gastric cancer", Am J Gastroenterol, 114, pp.71~79 (2019)
  93. Hamashima C, "A study protocol for expanding the screening interval of endoscopic screening for gastric cancer based on individual risks : prospective cohort study of gastric cancer screening", Ann Transl Med, 8, pp.1604~ (2020)
  94. Sonnenberg A, "Review article : historic changes of Helicobacter pylori-associated diseases", Aliment Pharmacol Ther, 38, pp.329~342 (2013)
  95. Wang C, "Changing trends in the prevalence of H. pylori infection in Japan(1908-2003) : a systematic review and meta-regression analysis of 170, 752individuals", Sci Rep, 7, pp.15491~ (2017)
  96. "Center for Cancer Control and Information Services" (2019)[URL]

관련 논문AI추천

Diagnosis and Management of High Risk Group for Gastric Cancer윤혁, 김나영거트앤리버 소화기연관학회협의회 · Gut and Liver2015 · 제9권 제1호Endoscopic Gastric Cancer Screening and Surveillance in High-Risk GroupsIl Ju Choi대한소화기내시경학회 · Clinical Endoscopy2014 · 제47권 제6호Current evidence of effects of Helicobacter pylori eradication on prevention of gastric cancer최일주대한내과학회 · The Korean Journal of Internal Medicine2013 · 제28권 제5호Screening for Gastric Cancer: The Usefulness of Endoscopy서민아, 최귀선대한소화기내시경학회 · Clinical Endoscopy2014 · 제47권 제6호Recent advancement in endoscopic diagnosis for risk stratification of gastric cancerChihiro Takeuchi, Dai Kubota, Daisuke Ohki, Hideki Nakagawa, Hikaru Kuribara, Hiroya Mizutani, Hiroyuki Hisada, Mitsuhiro Fujishiro, Naomi Kakushima, Nobutake Yamamichi, Ryohei Miyata, Seiichi Yakabi, Takuma Hiramatsu, Yosuke Tsuji, Yuko Miura대한소화기내시경학회 · Clinical Endoscopy2025 · 제58권 제6호Long-Term Effects of Helicobacter pylori Eradication on Metachronous Gastric Cancer Development오수연, Hyun Chae Jung, Jae Yong Park, Ji Min Choi, Joo Hyun Lim, Joo Sung Kim, Jung Kim, Sang Gyun Kim, Seung Jun Han거트앤리버 소화기연관학회협의회 · Gut and Liver2018 · 제12권 제2호

이 간행물의 다른 논문 (18건)

Bismuth-Based Quadruple Therapy for Clarithromycin-Resistant Helicobacter pylori Infection: Effectiveness and Cost-EfficiencyKim Gwang Ha, Lee Moon Wonpp. 807-808How to Optimize the Care Cascade of Hepatitis C Virus InfectionKim Beom Kyungpp. 809-810A New Paradigm Shift in Gastroparesis ManagementRerknimitr Rungsun, Mekaroonkamol Parit, Tiankanon Kaseneepp. 825-839Chemoprevention of Colitis-Associated Dysplasia or Cancer in Inflammatory Bowel DiseaseChen Yang-Yuan, Hsiao Shun-Wen, Yen Hsu-Hengpp. 840-848Prolonged QT Interval in Cirrhosis: Twisting Time?Lee William, Vandenberk Bert, Raj Satish R., Lee Samuel S.pp. 849-860
원문 보기